Ansell (AU:ANN)
ASX:ANN
Top Page
Ansell
(Sydney:ANN)
Select Model
Select Model
Rating:65Neutral
Price Target:
AU$31.00
▲(3.64% Upside)
Action:ReiteratedDate:03/26/26
The score is primarily supported by solid financial fundamentals and an attractive valuation (low P/E with a moderate dividend), reinforced by a generally positive earnings call with maintained guidance and strong margin/cash conversion. These positives are tempered by weak technicals (below major moving averages with negative MACD) and a decline in free cash flow growth.
Positive Factors
Margin Expansion
Sustained margin expansion reflects durable operational gains: procurement savings, pricing, and integration synergies improved gross and EBIT margins. Higher structural profitability increases cash flow per dollar of revenue, supporting reinvestment and resilience through commodity cycles.
Negative Factors
Decline in Free Cash Flow
A material fall in free cash flow growth weakens funding flexibility for capex, buybacks and M&A. With buybacks increasing net debt recently, persistent FCF deterioration could constrain strategic investments or force greater leverage, reducing long-term financial optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Expansion
Sustained margin expansion reflects durable operational gains: procurement savings, pricing, and integration synergies improved gross and EBIT margins. Higher structural profitability increases cash flow per dollar of revenue, supporting reinvestment and resilience through commodity cycles.
Read all positive factors
Ansell (ANN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.25B
Dividend Yield2.19%
Average Volume (3M)358.90K
Price to Earnings (P/E)9.3
Beta (1Y)1.16
Revenue Growth25.19%
EPS Growth18.82%
CountryAU
Employees15,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.94
Shares Outstanding142,930,880
10 Day Avg. Volume341,077
30 Day Avg. Volume358,899
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)1.47
Price to Sales (P/S)1.45
P/FCF Ratio17.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$38.59Price Target Upside29.02% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)1.43
Revenue Forecast (FY)AU$2.07B
Ansell Business Overview & Revenue Model
Company Description
Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare s...
How the Company Makes Money
Ansell makes money mainly by selling PPE products—especially protective gloves—into professional and institutional end-markets. Revenue is generated from the sale of disposable and durable/reusable gloves and other protective wear designed for spe...
Ansell Earnings Call Summary
Earnings Call Date:Feb 15, 2026
(Q2-2026)
| Next Earnings Date:Aug 25, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive operational and financial story: margins expanded materially (GPADE +220bps, EBIT margin +180bps to 14.3%), adjusted EPS and EBIT grew strongly and cash conversion was robust (112%). Management reported being on track to fully offset an $80M annualized U.S. tariff impact through pricing and mitigation, delivered KBU integration synergies and maintained FY26 EPS guidance of $1.37–$1.49 despite FX headwinds. Key challenges remain—tariff-driven market disruption in some regions (notably Mexico), volume declines in lower‑margin exam/commodity products, FX pressures and one-off integration/digital transformation costs—but these were positioned as manageable versus the company’s margin and cash strength.Positive Updates
Adjusted Sales Growth (after one-off removal)
Reported organic constant currency sales declined 0.6% in H1, but after removing $27M of prior-period one-off sales the company delivered adjusted organic sales growth of ~2.1% year-over-year.
Negative Updates
Reported Sales Decline and Volume Pressure
Reported organic constant currency sales were down 0.6% in H1 and certain lower‑margin/exam single-use volumes declined (medical exam glove volumes were a notable offset to sales), indicating some ongoing volume weakness in commodity product areas.
Read all updates
Q2-2026 Updates
Positive
Negative
Adjusted Sales Growth (after one-off removal)
Reported organic constant currency sales declined 0.6% in H1, but after removing $27M of prior-period one-off sales the company delivered adjusted organic sales growth of ~2.1% year-over-year.
Read all positive updates
Company Guidance
Management maintained FY26 adjusted EPS guidance of $1.37–$1.49, despite a roughly $5m FX headwind for the year (≈$1.5m H1, ≈$3.5m H2) and an annualized ~$80m U.S. tariff cost they say is on track to be fully offset by pricing and other mitigations; H1 adjusted EPS was $0.663 (almost 20% YoY), sales were down 0.6% organic CC but +2.1% on an adjusted basis after stripping a $27m one‑off, GPADE margin improved 220bps, EBIT grew 15.4% with margin up 180bps to 14.3%, cash conversion normalized at 112%, ROCE was 11.9% and ROE 10.1%; H1 net capex was $28m, significant items $7.3m, SG&A +0.4% with ~ $6m of KBU synergies, buybacks of $47m (net interest‑bearing debt up ≈$20m) left net debt/EBITDA at 1.5x and working capital ~ $23m lower versus June ’25.Ansell Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.07B | 2.00B | 1.62B | 1.63B | 1.85B | 2.04B |
| Gross Profit | 866.20M | 825.00M | 624.80M | 604.22M | 625.19M | 807.21M |
| EBITDA | 313.94M | 260.20M | 202.30M | 275.20M | 291.90M | 385.64M |
| Net Income | 138.74M | 101.60M | 76.50M | 148.30M | 158.70M | 246.70M |
Balance Sheet | ||||||
| Total Assets | 3.33B | 3.32B | 3.24B | 2.52B | 2.51B | 2.74B |
| Cash, Cash Equivalents and Short-Term Investments | 254.17M | 238.30M | 912.30M | 159.03M | 206.18M | 240.21M |
| Total Debt | 912.82M | 805.60M | 857.20M | 493.15M | 485.74M | 515.53M |
| Total Liabilities | 1.32B | 1.34B | 1.33B | 913.07M | 949.48M | 1.17B |
| Stockholders Equity | 1.97B | 1.96B | 1.89B | 1.60B | 1.54B | 1.55B |
Cash Flow | ||||||
| Free Cash Flow | 170.68M | 170.00M | 208.60M | 95.37M | 127.71M | 72.17M |
| Operating Cash Flow | 240.72M | 239.30M | 272.30M | 161.72M | 191.71M | 155.40M |
| Investing Cash Flow | -79.84M | -703.30M | -63.40M | -74.54M | -67.51M | -85.25M |
| Financing Cash Flow | -188.88M | -216.00M | 540.80M | -130.82M | -148.76M | -250.72M |
Ansell Technical Analysis
Neutral
29.91
Price Trends
30.80
Negative
32.93
Negative
32.46
Negative
Market Momentum
-0.58
Negative
53.50
Neutral
85.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ANN, the sentiment is Neutral. The current price of 29.91 is above the 20-day moving average (MA) of 28.97, below the 50-day MA of 30.80, and below the 200-day MA of 32.46, indicating a neutral trend. The MACD of -0.58 indicates Negative momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 85.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ANN.
Ansell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$47.76B | 21.91 | 24.81% | 0.95% | 11.99% | 32.89% | |
68 Neutral | AU$1.17B | 31.27 | 9.57% | ― | 15.60% | 58.74% | |
65 Neutral | AU$4.25B | 9.32 | 7.05% | 2.19% | 25.19% | 18.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$47.88M | -69.17 | -0.79% | ― | 17.82% | ― | |
47 Neutral | AU$61.04M | -59.43 | -1.32% | ― | 7.38% | 82.39% | |
43 Neutral | AU$36.32M | 7.24 | 8.71% | ― | 25.72% | 84.69% |
* Healthcare Sector Average
AU:ANN
Ansell
29.91
2.30
8.31%
AU:NAN
Nanosonics Limited
3.87
-0.76
-16.41%
AU:MVP
Medical Developments International Limited
0.43
-0.04
-7.61%
AU:TRJ
Trajan Group Holdings Ltd
0.40
-0.45
-53.22%
AU:CSX
CleanSpace Holdings Ltd.
0.46
0.06
15.00%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
33.01
-1.04
-3.04%
Ansell Corporate Events
Ansell Updates Market on Progress of On‑Market Share Buy‑Back
Mar 24, 2026
Ansell Limited has provided an updated notification to the ASX regarding its ongoing on‑market share buy‑back of ordinary fully paid shares. The company reported that a total of 1,910,265 shares had been repurchased prior to the latest...
Ansell Reports Daily Progress on Ongoing On‑Market Share Buy‑Back
Mar 23, 2026
Ansell Limited has updated the market with a daily notification on its ongoing on‑market share buy‑back program for its ordinary fully paid shares. The company reported that it had repurchased a cumulative total of 1,839,177 securities...
Ansell Updates Market on Progress of On-Market Share Buy-Back
Mar 22, 2026
Ansell Limited has continued its on-market share buy-back program, providing an updated notification to the ASX on March 23, 2026 regarding purchases of its ordinary fully paid shares. The update notes that a total of 1,636,342 shares had been bou...
Ansell Director Increases Indirect Shareholding via Voluntary Share Purchase Plan
Mar 20, 2026
Ansell has disclosed a change in the indirect shareholding of director Randy Stone, reflecting his participation in the company’s Voluntary Share Purchase Plan. Through an account held by CPU Share Plans Pty Ltd as trustee for the ANN VSP co...
Ansell Continues On-Market Share Buy-Back Program with Daily Updates
Mar 19, 2026
Ansell Limited has continued executing an on-market share buy-back program for its ordinary fully paid shares listed on the ASX under the code ANN. The company is using this initiative as part of its broader capital management strategy, signaling ...
Ansell Updates Market on Progress of On‑Market Share Buy‑Back
Mar 18, 2026
Ansell Limited has provided an updated notification to the ASX regarding its ongoing on‑market share buy‑back program for its ordinary fully paid shares. The update, dated 19 March 2026, confirms that a total of 1,411,576 shares had be...
Ansell Updates Market on Progress of On-Market Share Buy-Back
Mar 15, 2026
Ansell Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for ordinary fully paid shares. As of 16 March 2026, the company reported that it had repurchased a total of 1,317,947 shares pr...
Ansell logs ongoing on‑market buy‑back with daily share repurchases
Mar 9, 2026
Ansell Limited has continued its on-market share buy-back program, confirming in an updated Appendix 3C filing that a total of 1,072,051 ordinary fully paid shares had been repurchased prior to the latest trading day. The company reported that a f...
Ansell Updates Market on Progress of On‑Market Share Buy‑Back
Mar 8, 2026
Ansell Limited has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 980,151 shares had been repurchased prior to the most re...
Ansell reports lapse of restricted stock units and performance rights
Mar 3, 2026
Ansell Limited has reported changes to its issued capital, notifying the cessation of certain equity-based securities on its register. The update follows the formal lodgment of an Appendix 3H with the ASX, indicating adjustments to its outstanding...
Ansell Continues On-Market Share Buy-Back With New Daily Purchases
Feb 26, 2026
Ansell Limited has continued its on-market share buy-back program, reporting that a total of 921,486 ordinary fully paid shares had been repurchased prior to the latest trading day. On the previous day alone, the company bought back a further 58,6...
Ansell Updates Market on Daily Progress of On-Market Share Buy-Back
Feb 25, 2026
Ansell Limited has continued its on-market share buy-back of ordinary fully paid shares, as disclosed in its latest Appendix 3C update to the Australian Securities Exchange. The company reported that a cumulative total of 847,671 shares had been r...
Ansell Updates Market on Progress of Ongoing Share Buy-Back
Feb 24, 2026
Ansell Limited has disclosed an updated on-market share buy-back notification for its ordinary fully paid shares, as required by the ASX. The company reported that a total of 747,745 shares had been repurchased prior to the latest reporting day, w...
Ansell Updates Exchange Rate Details for FY26 Interim Dividend
Feb 24, 2026
Ansell Limited has updated its previous notification regarding the FY26 interim dividend for holders of its ordinary fully paid shares, advising the applicable exchange rate for the distribution tied to the six-month period ended 31 December 2025....
Ansell Director Randy Stone Acquires Shares Under Voluntary Purchase Plan
Feb 22, 2026
Ansell Limited has disclosed a change in director Randy Stone’s interests, with the executive acquiring 365 ordinary shares through the company’s Voluntary Share Purchase Plan. The transaction, valued at $11,780.16 and held indirectly ...
Ansell Reports Ongoing Daily On‑Market Share Buy‑Back Activity
Feb 19, 2026
Ansell Limited has provided an updated notification to the ASX confirming ongoing on-market share buy-backs of its ordinary fully paid shares under a program first announced in December 2025. The latest daily report, dated 20 February 2026, states...
Ansell Appoints Former Electrolux Chief Jonas Samuelson to Board
Jan 12, 2026
Ansell Limited has appointed Jonas Samuelson as an independent non-executive director, effective 1 March 2026, and invited him to join its Audit Compliance Committee. Samuelson, the former President and CEO of Electrolux Group, brings more than t...
Ansell Sets Date for FY26 Half-Year Results Amid CEO Transition
Jan 11, 2026
Ansell has announced it will release its half-year financial results for the period ended 31 December 2025 on 16 February 2026, accompanied by a webcast for investors and analysts. The presentation will feature both retiring CEO and Managing Direc...
Ansell Names Nathalie Ahlström as New CEO as Neil Salmon Retires
Jan 7, 2026
Ansell has announced that Managing Director and Chief Executive Officer Neil Salmon will retire after 13 years with the company, with former Fiskars Group CEO and President Nathalie Ahlström appointed as his successor. Ahlström will join...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.